Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luminespib + Trastuzumab in HER2+ Breast Cancer
NCT01271920Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2010
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of Luminespib in breast cancer, sponsored by Novartis. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Overall Response Rate. Started Sep 2010; status: completed.
02
Drugs
Luminespib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01271920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01271920.